Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 1,601–1,676 of 1,676
应红安, Gao, L., Liao, N., Xu, X., Yu, W., & Hong, W. (2022) · Figshare · doi:10.6084/m9.figshare.21557304
Additional file 1 of Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2024) · Figshare · doi:10.6084/m9.figshare.26624815
Additional file 5 of Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2024) · Figshare · doi:10.6084/m9.figshare.26624827
Williams, P. H., Huang, J., Rasmont, P., & An, J. (2016) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.192318
Additional file 3 of Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2024) · Figshare · doi:10.6084/m9.figshare.26624821
Qi, Y.-Y., Yan, L., Wang, Z.-M., Wang, X., Meng, H., Li, W.-B., Chen, D.-C., Li, M., Liu, J., & An, S.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13668158
Additional file 4 of Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2024) · Figshare · doi:10.6084/m9.figshare.26624824
Huh, J. H., Han, K.-D., Cho, Y. K., Roh, E., Kang, J. G., Lee, S. J., & Ihm, S.-H. (2022) · Figshare · doi:10.6084/m9.figshare.21485713
Gordon, S., Amar, M. J., Jeiran, K., Stagliano, M., Staller, E., Playford, M. P., Mehta, N. N., Vaisar, T., & Remaley, A. T. (2020) · Figshare · doi:10.6084/m9.figshare.12845703
Additional file 2 of Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2024) · Figshare · doi:10.6084/m9.figshare.26624818
Cardoso-Saldaña, G., Antonio-Villa, N. E., Martínez-Alvarado, M. R., González-Salazar, M. D. C., & Posadas‐Sánchez, R. (2024) · Figshare · doi:10.6084/m9.figshare.26747933
Koohi, F., Khalili, D., Mansournia, M. A., Hadaegh, F., & Soori, H. (2021) · Figshare · doi:10.6084/m9.figshare.14905926
Cardoso-Saldaña, G., Antonio-Villa, N. E., Martínez-Alvarado, M. R., González-Salazar, M. D. C., & Posadas‐Sánchez, R. (2024) · Figshare · doi:10.6084/m9.figshare.26747939
应红安, Gao, L., Liao, N., Xu, X., Yu, W., & Hong, W. (2022) · Figshare · doi:10.6084/m9.figshare.21557298
Ying, H., Gao, L., Liao, N., Xu, X., Yu, W., & Hong, W. (2022) · Figshare · doi:10.6084/m9.figshare.21557301
Chen, L., Zhao, Y., Wang, Z., Wang, Y., Bo, X., Jiang, X., Hao, C., Ju, C., Qu, Y., & Dong, H. (2023) · Figshare · doi:10.6084/m9.figshare.23700456
Qi, Y.-Y., Yan, L., Wang, Z.-M., Wang, X., Meng, H., Li, W.-B., Chen, D.-C., Li, M., Liu, J., & An, S.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13668161
Cardoso-Saldaña, G., Antonio-Villa, N. E., Martínez-Alvarado, M. R., González-Salazar, M. D. C., & Posadas‐Sánchez, R. (2024) · Figshare · doi:10.6084/m9.figshare.26747936
Deane, C. S., Phillips, B. E., Smith, K., Steele, A. M., Libretto, T., Statton, S. A., Atherton, P. J., & Etheridge, T. (2020) · Figshare · doi:10.6084/m9.figshare.12028242
Koohi, F., Khalili, D., Mansournia, M. A., Hadaegh, F., & Soori, H. (2021) · Figshare · doi:10.6084/m9.figshare.14905929
Awareness of young female for polycystic ovarian syndrome: a community survey
Kumari, K., Sonia, Hooda, A., et al. (2025) · Al-Azhar Assiut Medical Journal · doi:10.4103/azmj.azmj_7_25
Dislipidemias, ¿qué hay de nuevo?
Masson, W. (2015) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/rev.hosp.ital.b.aires.v35i3.715
Gu, T., Liu, J., Qi, Z., Zhang, Y., Hu, S., Zhang, Z., Xue, Z., Liu, T., & Chen, K. Y. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-025-02844-8
cHDL reevaluado: nuevos conocimientos y nuevo potencial en la farmacología cardiovascular
Fernández-Olmo, R., Cordero, A., Albarrán, O. G., Miranda, J. L., & Badimón, L. (2026) · REC CardioClinics · doi:10.1016/j.rccl.2025.12.004
Li, L., Deng, H., Xu, Z., Liu, Y., Zhang, X., Zhou, Q., Xiao, B., & Liu, H. (2026) · International Journal of Neuroscience · doi:10.1080/00207454.2026.2614748
“…disease [6]. however, there is a ‘paradox’ in the relationship between hDl-c and cardiovascular benefits. although observational studies show an inverse relationship between hDl-c and cardiovascular risk, intervention trials aimed at raising hDl-c have failed to reduce cardiovascular events [7–10].”
New therapeutic options for reducing atherosclerotic cardiovascular disease residual risk
Wong, N. D. (2021) · Srce i krvni sudovi · doi:10.5937/siks2104251w
Overview of the Study of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease
王, 然. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161286
Haddad, R. H., Al-Taani, B., Al-Tarakji, A., et al. (2026) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2026.2622973
“…and co‑administration with the DP1 receptor antagonist laropiprant, as tested in large cardiovascular outcome trials (aiM‑hiGh and hPs2‑thRiVe) [7]. although these approaches reduced flushing, hepatotoxicity, and lack of incremental car‑ diovascular benefit curtailed their widespread use,…”
El-Emamed, M. M. A., Ibrahim, M. A., Qelliny, M. R., Mostafa, M., Sayed, M. M. E., Kilany, M. S., Alsemeh, A. E., Moawad, R. S., & Mansour, M. F. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10286-z
“Also, HPS2-THRIVE (“[ 48]) found that the addition of niacin to statin therapy did not provide further cardiovascular benefits in individuals with atherosclerotic vascular disease.”
Chuang, S.-Y. C. S.-Y., Wu, M.-T., Chung, R.-H., Lai, C. H., Cheng, W.-J., Liu, W.-L., Hsiung, C. A., Chuang, S., I-Chien, W., & Hsu, C. Y. (2026) · medRxiv · doi:10.64898/2026.01.30.26345249
Management and Therapy of Dyslipidemia
Marschang, P. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_23
New insights into the treatment of hyperlipidemia: An expert review
Tomlinson, B. (2026) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-25-00051
HDL and Cardiovascular Disease: Mechanisms, Therapeutic Advances, and Challenges
Sen, K., & Sinha, A. (2026) · Proceedings of the Zoological Society · doi:10.1007/s12595-026-00609-4
Tomlinson, B. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642210 · Cited by 2
“It was thought that a major benefit of niacin was its effect on increasing HDL-C and this was tested in the AIM-HIGH and the HPS2-THRIVE studies [33,34].”
Zhang, X., Yang, B., Boden-Albala, B. M., Anton‐Culver, H., Allison, M., Horn, L. V., Madsen, T. E., Malik, S., Manson, J. E., Neuhouser, M. L., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101534 · Cited by 1
“Dietary niacin intake observed in our study was modest relative to the pharmacologic doses used in trials such as AIM-HIGH [24] and HPS2-THRIVE [25], which failed to demonstrate cardiovascular benefit from niacin supplementation.”
Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights
Rojo-López, M. I., Niño-Narvión, J., Antentas, M., Fernández‐Camins, B., Martínez-Rojo, E., Poca, M., Martínez‐Sánchez, M. A., Ramos‐Molina, B., Rossell, J., Mauricio, D., et al. (2026) · Nutrients · doi:10.3390/nu18060996
Balasooriya, C. M., Jennings, C. S., Kenny, E., Bacquer, D. D., Ray, K. K., Corry, J.-P., Adamska, A., Kotseva, K., McEvoy, J. W., Noone, C., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101576
“Although niacin remains the only agent to significantly raise HDL-C, large-scale trials such as AIM-HIGH and HPS2-THRIVE demonstrated no ASCD benefit, and niacin was subsequently withdrawn from the European market due to safety concerns and lack of efficacy[12].”
Nasim, N., & Raana, T. (2026) · medtigo Journal of Medicine · doi:10.63096/medtigo3062426
Clinical Assessment of Anti-Atherogenic Function of HighDensity Lipoprotein (HDL)
Ma, F. (2018) · theses.fr (ABES) · doi:10.70675/aec01babza8edz47a2zb4d4zc7c3be00b185
Omics of human plasma lipoproteins : role in cardiometabolic diseases
Zakiev, E. (2019) · theses.fr (ABES) · doi:10.70675/d80fee25za2f2z4790z9eb9ze82d5514a198
Clinical Trials in Cardiovascular Medicine
Nogueira, A., Zimerman, A., & Moura, F. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00091-1
Approches biochimique, épidémiologique et clinique du métabolisme intégré de la Lipoprotéine (a)
Blanchard, V. (2020) · theses.fr (ABES) · doi:10.70675/3ce7e0fdzecbaz4b18zaf08z34fb33c163ff · Cited by 1
Rezki, A. (2019) · theses.fr (ABES) · doi:10.70675/392902d9z7810z4025zb9afz3081c32bac5d
Mian, N., Hayat, K., Ullah, S., et al. (2026) · medtigo Journal of Medicine · doi:10.63096/medtigo30624116
Zhang, F., & Liao, Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1790509 · Cited by 3
喻, 慧. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1651815
Repositioning of niacin in atherosclerotic cardiovascular disease
Li, W., Bai, Z., Li, C., Lu, S., Wang, Y., Huang, D., Zhang, H., Yuan, J., Zhen, X., & Liu, Y. (2026) · PharmaNutrition · doi:10.1016/j.phanu.2026.100506
Metabolic Implications in Cardio-Renal Syndromes
Timar, B., Gaiţă, L., Avram, V. F., & Braha, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-25434-4_15
Masrouri, S., Ebrahimi, N., Molavizadeh, D., Esmaeili, F., Azizi, F., & Hadaegh, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104805
Tsai, Y., Mudiyanselage, S. P. K., Tsai, Y., Maithreepala, S. D., Liu, W.-C., Ko, N., Yeh, J., Wei-Lin, C., Hsu, P.-I., Chou, C., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02208-x · Cited by 1
“…early because of the absence of incremental cardiovascular benefit and a possible increase in ischemic stroke risk [22], and the HPS2-THRIVE trial, which demonstrated no reduction in major vascular events together with increased serious adverse events associated with niacin-based therapy [23].”
Raygani, S., & Wilkinson, M. J. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.06.025
Yi, Y., Luo, Y., Deng, Y., Guo, X., Liu, W. T., Liu, Y., Yu, B. Q., Zhao, Y., & Peng, D. Q. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.07.008
Lipoprotein(a) in Cardiovascular Disease Prevention: Current and Emerging Therapeutic Approaches
Osei, J., Bennett, J., Raval, O., Seo, G., Eisenberg, S. D., Nyenhuis, R., Gershon, G., Stresemann, S., Akkaya, S., Bhattacharya, A., et al. (2026) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-026-01149-y
“Niacin lowers Lp(a) by approximately 20–30% in addition to its effects on LDL-C and HDL-C, yet conferred no incremental cardiovascular benefit when added to statin therapy in the AIM-HIGH and HPS2-THRIVE trials, while increasing adverse events [63, 64 ].”
A Niacin−α-Lipoic Acid Hybrid Ameliorates Alzheimer’s Disease Pathology in Mouse Models
Peng, W., Wei, C., Liu, J., Pi, J., Ding, C., Guo, H., Chen, X. Y., Lu, J., Liu, R., Yin, W., et al. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00162
Animati, F. M., Proietti, S., Auletta, F., Montone, R. A., Cappannoli, L., Fracassi, F., Gaspardone, A., & Burzotta, F. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155897
Lp(a) in chronic kidney disease: state of the art and management perspectives
Spatola, L., Maccarrone, R., Zeiler, M., & Granata, A. (2026) · Journal of Nephrology · doi:10.1093/joneph/aajag084
Inflammation and the Heart: The Role of Traditional Factors
Cheraghi, M., Amin, A., Jabarzare, S., Sabooteh, T., Moradi, P., Dehghani, M., Sedighi, M., Hatami, F., Rafieian, A., & Farshidfar, T. (2026) · Cardiology Research and Practice · doi:10.1155/crp/4623305
The safety of low lipoprotein(a): a story not yet fully told
Schwartz, G. G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag565 · Cited by 1
Ibrahim, E., Alaasmi, A., Mbionwu, U., Lastra, G., & Manrique‐Acevedo, C. (2026) · Physiology in health and disease · doi:10.1007/978-3-032-26472-5_9
Novel Lipoprotein (a) Therapies: A Comprehensive Review
Ebubechukwu, U. J., Ugoala, O. S., Shahid, R., & Kulkarni, A. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01453-9 · Cited by 2
“Outcome trials (AIM-HIGH and HPS2-THRIVE) showed no incremental car - diovascular benefit and significant side effects (flushing, liver toxicity, new-onset diabetes, myopathy) [20 , 21 ].”
Syed, A. B., Michalak, S., Potulapati, I., Vignarajah, A., & Shah, G. V. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176640
“Due to lack of outcome benefit and adverse effects, it is not recommended solely for Lp(a) reduction [22,23].”
Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies
Miramontes‐González, J. P. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00825-5 · Cited by 1
Pedro‐Botet, J., Argüeso, R. M., Díaz, Á., Millán, J., Pascual, V., Pérez‐Martínez, P., Pintó, X., Ruiz‐García, A., & Díaz-Díaz, J. L. (2026) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2026.500961
Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention
Bene-Alhasan, Y. O., Nambi, V., Abushamat, L. A., & Ballantyne, C. M. (2026) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1836
Lipoprotein(a) in the statin era: from risk marker to therapeutic target
Hong, R., 刘玉华, 李晓春, Liu, H., & 谢东阳 (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1938864
“Yet in statin-treated patients neither AIM-HIGH nor HPS2-THRIVE showed any reduction in cardiovascular events, and the latter caused clear harm, definitively closing the niacin pathway (Boden et al., 2011; Landray et al., 2014).”
Ma, T., Hu, X., Xue, B., Pan, X., Zang, J., Huang, R., Zhang, Y., Chu, L., Yan, W., Li, J., et al. (2026) · Cardiology Plus · doi:10.1097/cp9.0000000000000170
Thandi, P., Pradhan, A. K., Agarwala, R., Puri, R., & Perrone, M. A. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.88
Lipoprotein(a) management simplified: The National Lipid Association lipid simplified series
Koschinsky, M. L., & Ballantyne, C. M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.013 · Cited by 1
Zhu, J., Li, J., Qin, Y., Cui, Y., & Mou, L. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuag128
Lipoprotein (a): from molecular structure features to diagnostic and treatment approaches
Skybchyk, V. А., Kysil, O. Y., Labinska, O., & Halkevych, M. (2026) · Acta Medica Leopoliensia · doi:10.25040/aml2026.1-2.030
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
“In the setting of modern statin therapy, niacin has also failed to show consistent additional ASCVD outcome benefits [ 392, 393 ].”
Eldaidamouni, A. A., hasan, M., Medina‐Inojosa, J. R., Razavi, A. C., Subramaniyam, V., Alkhoder, A. A., Bennett, J., Ko, Y., Liu, C., YADALAM, A. K., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.102089
Widjaja, J. S., Adji, A. S., Baraja, A., Dharmasaputra, A., Rosyadi, R. N., Komalasari, I., Mustofa, A., Multazam, C. E. C. Z., Alkaff, F. F., & Saputra, P. B. T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179420
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.